Status:
COMPLETED
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
Lead Sponsor:
AstraZeneca
Conditions:
Bronchiectasis
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Bronchiectasis (Brx) and if so how it compares to placebo (a substance which does not have an...
Eligibility Criteria
Inclusion
- Female of non child bearing potential
- Clinical diagnosis of bronchiectasis
- Be sputum producers, with history of chronic expectoration on most days
Exclusion
- Concomitant diagnosis of pulmonary disease other than bronchiectasis or COPD
- FEV1 of \<30% of predicted normal
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00769119
Start Date
September 1 2008
End Date
April 1 2009
Last Update
August 20 2012
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Chemin Sainte-Foy, Quebec, Canada
2
Research Site
Calgary, Canada
3
Research Site
Montreal, Canada
4
Research Site
Ontario, Canada